Background: Conventional antitumor Photosensitizers (PS) are normally low toxic in the dark
whereas light activation triggers massive cell death (photodynamic therapy, PDT).
Objective: To expand the therapeutic potential of PS to dual potency cytocidal agent, taking advantage of the
use of bacteriopurpurin for a deeper tissue penetration of light, and suitability of the tetrapyrrolic macrocycle for
chemical modifications at its periphery.
Methods: Conjugation of a pro-oxidant thiolate Au (I) moiety to the bacteriopurpurin core and evaluation of
cytotoxicity in cell culture and in vivo.
Results: New water-soluble derivatives showed micromolar cytotoxicity for cultured human tumor cell lines in
the dark, including the subline with an altered drug response due to p53 inactivation. Cellular PDT with the
selected conjugate, thiolate Au (I)-dipropoxybacteriopurpurinimide (compound 6) with two triphenylphosphine
Au fragments, triggered rapid (within minutes) cell death. Damage to the plasma membrane (necrosis) was a
hallmark of cell death by compound 6 both in the dark and upon light activation. Furthermore, one single i.v.
injection of compound 6 caused retardation of transplanted syngeneic tumors at the tolerable dose. Illumination
of tumors that accumulated compound 6 significantly synergized with the effect of 6 in the dark.
Conclusion: Complexes of virtually non-toxic, photoactivatable bacteriopurpurin with the gold-containing
organic moiety are considered the dual potency antitumor agents, tentatively applicable for intractable tumors.